Search
Filter Results
Displaying 41–50 of 999 results
-
Aug 23, 2024
Eye on the Cure Podcast | Episode 72: Hannah Scanga
Hannah Scanga talks about the basics of genetic testing and counseling, and more.
-
Aug 21, 2024
Foundation Fighting Blindness Comments on Proposed NIH Reforms
The Foundation responds to the U.S. House of Representatives Energy and Commerce Committee on the framework for reforming the National Institutes of Health
-
Aug 14, 2024
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Aug 9, 2024
Eye on the Cure Podcast | Episode 71: Dr. Leonide Saad
Dr. Saad discusses an emerging therapy for Stargardt disease that has performed well in clinical trials.
-
Aug 6, 2024
A Para Triathlete's Journey With Stargardt
This exclusive Beacon Story podcast features WROC’s Adam Chodak and professional Para triathlete Deb Chucoski as they discuss living with Stargardt disease and the amazing achievements of those who refuse to let it define them.
-
Aug 5, 2024
Maverick, a determined and adventurous 10-year-old, was diagnosed with X-linked retinoschisis (XLRS) at age six, which led his family to find support and resources through the Foundation Fighting Blindness. Since his diagnosis, Mav continues to pursue his passions in sports and outdoor activities, inspiring his family with his resilience and positive attitude.
-
Zoom is a cloud-based video communications app that allows you to set up virtual video and audio conferencing, webinars, live chats, screen-sharing, and other collaborative capabilities.
-
Many users find that using an external keyboard with keyboard shortcuts for Microsoft Teams on Windows helps them work more efficiently. For users with mobility or vision disabilities, keyboard shortcuts can be easier than using the touchscreen and are an essential alternative to using a mouse.
-
Foundation News from the Foundation Fighting Blindness.
-
Jul 30, 2024
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Previously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease